Foresite Capital Management IV, LLC 13F holdings
Foresite Capital Management IV, LLC reported 6 positions with a total reported value of $290.2M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: PHVS Pharvaris N.V. (57.0%), CYTK CYTOKINETICS INC (21.0%), EIKN Eikon Therapeutics, Inc. (8.7%), RLAY Relay Therapeutics, Inc. (8.1%), XENE Xenon Pharmaceuticals Inc. (3.3%). Against 2026-03-31 it opened 1 new position and exited 3. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Foresite Capital Management IV, LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| PHVS Pharvaris N.V. | 4,778,581 | $165.2M | 57.0% |
| CYTK CYTOKINETICS INC | 714,695 | $60.9M | 21.0% |
| EIKN Eikon Therapeutics, Inc. | 1,943,682 | $25.4M | 8.7% |
| RLAY Relay Therapeutics, Inc. | 1,250,000 | $23.4M | 8.1% |
| XENE Xenon Pharmaceuticals Inc. | 160,000 | $9.7M | 3.3% |
| CRNX Crinetics Pharmaceuticals, Inc. | 150,000 | $5.6M | 1.9% |
New positions this quarter
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| CRNX Crinetics Pharmaceuticals, Inc. | 150,000 | $5.6M | 1.9% |
Sold out
Biggest increases and decreases
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| CYTK CYTOKINETICS INC | 503,295 | 714,695 | +42.0% | $60.9M |
| RLAY Relay Therapeutics, Inc. | 1,000,000 | 1,250,000 | +25.0% | $23.4M |
Decreases
No position was decreased.

